American College of Education and Norman Regional Health System Honor Nurses During National Nurses Week
Press Releases American College of Education and Norman Regional Health System Honor Nurses During National Nurses Week
ACE and Norman Regional honor nurses' vital role as the heartbeat of healthcare with safety-focused recognition.
In celebration of National Nurses Week, American College of Education (ACE) has partnered with Norman Regional Health System to honor the vital role nurses play as the "heartbeat of healthcare." Together, ACE and Norman Regional recognize the compassion, resilience and dedication that nurses bring to their patients and each one of our communities.
As part of this celebration, ACE is sponsoring personal safety keychain alarms for around 1,200 Norman Regional nurses, known as "healers." This gift goes beyond traditional workplace recognition - it acknowledges that nurse safety and well-being matter, on and off the clock. These personal alarms offer a simple, immediate tool for self-protection, whether they're commuting late, working high-stress shifts, or operating in vulnerable environments. By providing these practical devices, ACE and Norman Regional hope to champion a culture of safety, advocacy and deep respect for the people at the heart of healthcare.
"At American College of Education, we believe supporting nurses means caring for all aspects of their lives - not just their work," said Geordie Hyland, ACE's president and CEO. "Through our partnership with Norman Regional, we are honoring their dedication and advocating for their safety, and we're proud to champion their well-being."
As ACE's first healthcare partner through its Credit for Prior Learning (CPL) initiative, Norman Regional shares a commitment to uplifting healthcare professionals at every stage of their careers.
"The ACE partnership has been a game changer for our healers. The ability to access continuing education toward their degree aspirations is going to not only impact their lives, but the generations who will follow them," said Norman Regional's Chief People Officer Keith Minnis, SPHR, SHRM-SCP. "Norman Regional is very blessed and grateful for the partnership with ACE and encourages other healthcare systems to consider partnering with ACE for their employees."
Through the CPL program, nurses can translate their real-world experience into academic credit, accelerating their educational journeys while honoring the expertise they bring to the field. Together, ACE and Norman Regional are creating opportunities for nurses to grow their careers, strengthen their impact, and continue serving their communities with compassion and excellence.
"Advancing personal and professional growth is crucial in supporting our healers here at Norman Regional. Not only does our partnership with ACE help to remove barriers for healers wanting to continue their education, but it also creates opportunities to invest in the future of the health system by fostering a skilled workforce that adapts to evolving industry standards and ultimately provides better patient outcomes," said Lindsay Birdwell, MSN, RN, CEN, Norman Regional's education specialist and student coordinator.
ACE's sponsorship reflects its broader mission to support those who serve others, recognizing that nurses not only heal individuals - they strengthen the fabric of our entire community. As the heartbeat of healthcare, nurses represent the best of resilience, care and hope for a healthier tomorrow.
About American College of Education
American College of Education (ACE) is an accredited, fully online college specializing in high-quality, affordable programs in education, business, leadership, healthcare and nursing. Headquartered in Indianapolis, ACE offers more than 60 innovative and engaging programs for adult students to pursue a doctorate, specialist, master's or bachelor's degree, along with graduate-level certificate programs.
About Norman Regional Health System
Norman Regional Health System is a multi-campus health system making its community stronger in south central Oklahoma through compassionate and leading-edge care. Norman Regional Health System's flagship location, Norman Regional Hospital, is a newly expanded 775,000 square-foot acute-care hospital in Norman, OK. Norman Regional Hospital, located at I-35 and Tecumseh Road, is licensed for 305 beds and offers a complete range of services. Norman Regional also operates two freestanding emergency room plus facilities: Norman Regional Moore on I-35 in Moore and Norman Regional Nine in southeast Norman. In total, Norman Regional is comprised of one acute-care hospital, two freestanding emergency room plus facilities, three urgent care locations and multiple primary care and specialty care clinics, diagnostic imaging, and laboratories. It also owns and operates EMSSTAT, the emergency services providers for Norman, Moore and unincorporated areas of Cleveland County.
Contact Information
Maria Penaloza
Media & Content Strategy Manager
maria.penaloza@issuerdirect.com
This story was originally published May 6, 2025 at 8:06 AM.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 hours ago
- Yahoo
Sam's Club says it plans to remove synthetic dyes from private brand by end of 2025
BENTONVILLE, Ark. (KNWA/KFTA) — Sam's Club announced on Thursday plans to eliminate more than 40 ingredients from its private label brand, Member's Mark, by the end of the year. The wholesale chain said in a news release that under the initiative, 'Made Without,' it will alter its food and beverage products to offer items without certain ingredients in order to cater to specific dietary preferences. In April, U.S. Health Secretary Robert F. Kennedy Jr. and Food and Drug Administration Commissioner Marty Makary announced plans to phase out several types of artificial, petroleum-based dyes used as food coloring in various snacks, drinks and desserts that line grocery shelves, mainly citing kids' health as the reason for the move. 'We take pride in the high-quality ingredients that go into our products, but what truly differentiates us are the ingredients we consciously leave out,' Julie Barber, chief merchant at Sam's Club, said. 'Our 'Made Without' commitment underscores our aspiration to be members' go-to destination for quality at a disruptive value. For us, it's about listening to our members and providing the items that resonate with their lifestyles.' Here is the list of ingredients Sam's Club plans to eliminate from its 'Made Without' products: Acesulfame-K (Acesulfame Potassium) (Ace-K) Acetylated Ester of Mono & Diglycerides (ACETEM) Artificial Flavors Aspartame Azodicarbonamide (ADA) Benzyl Alcohol Butylated hydroxy anisole (BHA) Butylated Hydroxytoluene (BHT) Butylparaben Certified Synthetic Colors/FD&C Colors Cocamide DEA Cyclamates Cyclopentasiloxane Cyclotetrasiloxane Dioctyl Sodium Sulfosuccinate (DSS) DMDM Hydantoin Ethyl Vanillin Formaldehyde Hexa, Hepta, Octa Esters of Sucrose High Fructose Corn Syrup Lactylated Esters of Mono & Diglycerides (OLEON) Methylparaben Neotame Phthalates Potassium Bisulfate Potassium Bisulfite Potassium Nitrate/Nitrite Propyl Gallate Propylparaben Saccharin (All) Simplesse Sodium Ferrocyanide Sodium Propionate Sucroglycerides Sucrose Polyester Talc Tertiary Butylhydroquinone (Except for our 35-pound food service frying oils) Toluene Sam's Club said it has already released cookies and other snacks without artificial colors. The retailer is also offering fresh sushi as part of its 'Made Without' program. In addition to Sam's Club, Tyson recently announced it planned to eliminate synthetic dyes from its products, according to CEO Donnie King. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
a day ago
- Yahoo
Acerand Therapeutics Initiates First-in-Human Phase I Clinical Trial of ACE-232, a Novel CYP11A1 Inhibitor for Advanced Prostate Cancer
SHANGHAI & INDIANAPOLIS, June 05, 2025--(BUSINESS WIRE)--Acerand Therapeutics, a clinical-stage biotech company focusing on the discovery and development of innovative small-molecule therapies in oncology, today announced the dosing of the first patient in its first-in-human Phase I clinical trial (NCT06801236) of ACE-232, a novel oral inhibitor of CYP11A1. The trial is being conducted in patients with metastatic castration-resistant prostate cancer (mCRPC). This multicenter Phase I study is being conducted in both the United States and China. The study comprises two parts: a dose-escalation phase (Phase IA) and a dose-optimization phase (Phase IB). The primary objectives are to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), as well as preliminary clinical activity of ACE-232, and to determine the recommended Phase II dose (RP2D). Professor Emmanuel Antonarakis, Director of Genitourinary Oncology at Masonic Cancer Center, University of Minnesota, is serving as the global coordinating Principal Investigator for the study. "I would like to congratulate the Acerand team, the research staff, and the first patient for helping us to reach this important milestone," says Dr. Antonarakis. Preclinical data demonstrated that ACE-232 possesses superior potency, efficacy, and pharmacokinetic properties (flat PK curve and long half-life profile) compared to other investigational CYP11A1 inhibitors, including MK-5684 (Opevesostat, formerly known as ODM-208). ACE-232 showed excellent tolerability in preclinical models, presenting a wide therapeutic window for clinical development. The initiation of this trial marks a significant milestone for Acerand, representing its first clinical study in the United States and highlighting its strategic commitment to the global development of innovative cancer therapies that address major unmet medical needs. About ACE-232 ACE-232 is a highly potent and selective small-molecule inhibitor of CYP11A1, a key adrenal enzyme involved in the first and rate-limiting step of steroid hormone biosynthesis. By targeting CYP11A1, ACE-232 aims to suppress the production of androgens and other steroid hormones, offering a novel therapeutic mechanism for the treatment of androgen-dependent (including enzalutamide or abiraterone-resistant) prostate cancer. About Acerand Therapeutics Acerand Therapeutics is a biotech company dedicated to discovering and developing novel small-molecule therapies for oncology and metabolic diseases. With research and development hubs in Shanghai, China, and Indianapolis, USA, ACE-232 leverages its proprietary innovation platform and operational efficiency to deliver a highly differentiated pipeline of drug candidates from discovery to clinical trials. View source version on Contacts Acerand Therapeuticsinfo@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Acerand Therapeutics Initiates First-in-Human Phase I Clinical Trial of ACE-232, a Novel CYP11A1 Inhibitor for Advanced Prostate Cancer
SHANGHAI & INDIANAPOLIS, June 05, 2025--(BUSINESS WIRE)--Acerand Therapeutics, a clinical-stage biotech company focusing on the discovery and development of innovative small-molecule therapies in oncology, today announced the dosing of the first patient in its first-in-human Phase I clinical trial (NCT06801236) of ACE-232, a novel oral inhibitor of CYP11A1. The trial is being conducted in patients with metastatic castration-resistant prostate cancer (mCRPC). This multicenter Phase I study is being conducted in both the United States and China. The study comprises two parts: a dose-escalation phase (Phase IA) and a dose-optimization phase (Phase IB). The primary objectives are to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), as well as preliminary clinical activity of ACE-232, and to determine the recommended Phase II dose (RP2D). Professor Emmanuel Antonarakis, Director of Genitourinary Oncology at Masonic Cancer Center, University of Minnesota, is serving as the global coordinating Principal Investigator for the study. "I would like to congratulate the Acerand team, the research staff, and the first patient for helping us to reach this important milestone," says Dr. Antonarakis. Preclinical data demonstrated that ACE-232 possesses superior potency, efficacy, and pharmacokinetic properties (flat PK curve and long half-life profile) compared to other investigational CYP11A1 inhibitors, including MK-5684 (Opevesostat, formerly known as ODM-208). ACE-232 showed excellent tolerability in preclinical models, presenting a wide therapeutic window for clinical development. The initiation of this trial marks a significant milestone for Acerand, representing its first clinical study in the United States and highlighting its strategic commitment to the global development of innovative cancer therapies that address major unmet medical needs. About ACE-232 ACE-232 is a highly potent and selective small-molecule inhibitor of CYP11A1, a key adrenal enzyme involved in the first and rate-limiting step of steroid hormone biosynthesis. By targeting CYP11A1, ACE-232 aims to suppress the production of androgens and other steroid hormones, offering a novel therapeutic mechanism for the treatment of androgen-dependent (including enzalutamide or abiraterone-resistant) prostate cancer. About Acerand Therapeutics Acerand Therapeutics is a biotech company dedicated to discovering and developing novel small-molecule therapies for oncology and metabolic diseases. With research and development hubs in Shanghai, China, and Indianapolis, USA, ACE-232 leverages its proprietary innovation platform and operational efficiency to deliver a highly differentiated pipeline of drug candidates from discovery to clinical trials. View source version on Contacts Acerand Therapeuticsinfo@
